Early and late effects of highly active antiretroviral therapy: A 2 year follow-up of antiviral-treated and antiviral-naive chronically HIV-infected patients

AIDS

Volumn 16, Issue 13, 2002, Pages 1767-1773

  Clerici, Mario ^a   Seminari, Elena ^a   Maggiolo, Franco ^a   Pan, Angelo ^a   Migliorino, Marco ^a   Trabattoni, Daria ^a   Castelli, Francesco ^a   Suter, Fredy ^a   Fusi, Maria Luisa ^a   Minoli, Lorenzo ^a   Carosi, Giampiero ^a   Maserati, Renato ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Cytokines; HAART; HIV; IL 7; Immunology; Virology

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CD8 ANTIGEN; CHEMOKINE; GAMMA INTERFERON; GLYCOPROTEIN GP 160; INTERLEUKIN 2; INTERLEUKIN 7;

ADULT; ARTICLE; CLINICAL ARTICLE; CYTOKINE PRODUCTION; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; MALE; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT OUTCOME; VIREMIA; VIRUS INHIBITION; VIRUS REPLICATION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD8-POSITIVE T-LYMPHOCYTES; CHRONIC DISEASE; CYTOKINES; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-1; HUMANS; INTERLEUKIN-7; LONGITUDINAL STUDIES; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VIRAL LOAD; VIREMIA;

EID: 18644382965     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200209060-00009     Document Type: Article

References (43)

1. Plana M, Garcia F, Gallart T, et al. Immunological benefits of antiretroviral therapy in very early stages of asymptomatic chronic HIV-1 infection. AIDS 2000, 14:1921-33.
2. Kelleher AD, Carr A, Zaunders J, Cooper DA. Alterations of the immune response of HIV-infected subjects treated with an HIV-specific protease inhibitor, Ritonavir. J Infect Dis 1996, 173:321-329.
3. Autran B, Carcelain G, Li TS, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997, 277:112-116.
4. Angel JB, Kumar A, Parato K, et al. Improvement in cell-mediated immune function, during potent anti-human immunodeficiency virus therapy with ritonavir plus saquinavir. J Infect Dis 1998, 177:808-904.
5. Li TS, Tubiana R, Katlama C, Calvez V, Ait Mohand H, Autran B. Long-lasting recovery in CD4 T cell function and viral load reduction after HAART in advanced HIV-1 disease. Lancet 1998, 351:1682-1686.
6. Lederman MM, Connick E, Landay A, et al. Immunologic responses associated with 12 weeks of combination therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS clinical trial group protocol 315. J Infect Dis 1998, 178:70-79.
7. Kaufmann GR, Bloch M, Zaunders JJ, et al. Long-term immunological response in HIV-1 infected subjects receiving potent antiretroviral therapy. AIDS 2000, 14:959-969.
8. Pontesilli O, Kerkhof-Garde S, Notermans DW, et al. Functional T cell reconstitution and human immunodeficiency virus-1-specific cell-mediated immunity during highly active antiretroviral therapy. J Infect Dis 1999, 180:76-86.
9. Gotch FM, Rowland-Jones S, Nixon DF. Longitudinal studies of HIV gag-specific cytotoxic T lymphocyte responses over time in several patients. In: Cytotoxic T cells in HIV infection. Racz P, Letvin NL, Gluckman JC (editors). Basel: Karger; 1992. pp. 60-72.
10. Keet IPM, Krol A, Klein MR, et al. Long-term asymptomatic HIV-1 infection with normal and low CD4 counts. J Infect Dis 1994, 169:1236-1241.
11. Riviere Y, McChesney MB, Porrot F, et al. Gag-specific cytotoxic responses to HIV type 1 are associated with a decreased risk of progression to AIDS-related complex or AIDS. AIDS Res Hum Retrovir 1995, 11:903-907.
12. Clerici M, Balotta C, Trabattoni D, et al. Human immunodeficiency virus (HIV) phenotype and interleukin-2/interleukin-10 ratio are associated markers of protection and progression in HIV infection. Blood 1996; 88:574-579.
13. Rosenberg ES, Billingsley JM, Caliendo AM, et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 1997, 278:147-150.
14. Clerici M, Seminari E, Suter F, et al. Different immunologic profiles characterize HIV infection in HAART-treated and antiretroviral-naive patients with undetectable viremia. AIDS 2000, 4:109-116.
15. de Jong M, de Boer RN, de Wolf F, et al. Overshoot of HIV-1 viremia after discontinuation of antiretroviral treatment. AIDS 1997, 1:F79-F84.
16. Montaner JSG, Harris M, Mo T, Harrigan PR. Rebound of HIV plasma viremia following prolonged suppression with combination therapy. AIDS 1998, 12:1398-1399.
17. Harrigan PR, Whaley M, Montaner JSG. Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy. AIDS 1999, 13:F59-F62.
18. Garcia F, Plana M, Vidal C, et al. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy. AIDS 1999, 13:F79-F86.
19. Pialoux G, Raffi F, Brun-Vezinet F, et al. A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously naive HIV-1-infected patients. N Engl J Med 1998, 339:1269-1276.
20. Havlir DV, Marschner IC, Hirsch MS, et al. Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. N Engl J Med 1998, 339:1261-1268.
21. Reijers MH, Weverling GJ, Jurriaans S, et al. Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study. Lancet 1998, 352:185-190.
22. Levy JA. Caution: should we be treating HIV infection early? Lancet 1998, 352:982-983.
23. Cooper DA. Therapeutic strategies for HIV infection. Time to think hard. N Engl J Med 1998, 339:1297-1299.
24. Clerici M, Stocks NI, Zajac RA, et al. IL-2 production permits detection of antigenic peptide recognition by T helper lymphocytes from asymptomatic, HIV seropositive individuals. Nature 1989, 339:383-386.
25. Angel JB, Parato KG, A Kumar, et al. Progressive human immunodeficiency virus-specific immune recovery with prolonged viral suppression. J Infect Dis 2001, 185:546-554.
26. Blankson JN, Gallant JE, Siliciano RF. Proliferative responses to human immunodeficiency virus type 1 antigens in HIV-1-infected patients with immune reconstitution. J Infect Dis 2001, 183:657-661.
27. Levitz SM. Improvement in CD4+ T cell counts despite persistently detectable HIV viral load. N Engl J Med 1998, 338:1074-1075.
28. Kauffman D. CD4 cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Lancet 1998, 351:723-724.
29. Havlir DV, Bassett R, Leviatan R, et al. Prevalence and predictive of intermittent viremia with combination HIV therapy. JAMA 2001, 286:171-179.
30. Kalams SA, Goulder PJ, Shea AK, et al. Levels of HIV-1-specific cytotoxic T lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral theraphy. J Virol 1999, 73:6721-6728.
31. Rinaldo CR Jr, Huang XL, Fan Z, et al. Anti-human immunodeficiency virus type 1 (HIV-1) CD8(+) T-lymphocyte reactivity during combination antiretroviral therapy in HIV-1-infected patients with advanced immunodeficiency. J Virol 2000, 74:4127-4138.
32. Plana M, Garcia F, Gallart T, et al. Immunological benefits of antiretroviral therapy in very early stages of asymptomatic chronic HIV-1 infection. AIDS 2000, 14:1921-1933.
33. Seth A, Markee J, Hoering A, et al. Alterations in T cell phenotype and HIV-1 specific cytotoxicity after potent antiretroviral therapy. J Infect Dis 2001, 183:722-729.
34. Schmitz JE, Kuroda MJ, Santra S, et al. Control of viremia in simian immunodeficiency virus infection by CD8+ T lymphocytes. Science 1999, 283:857-860.
35. Brodie SJ, Lewinsohn DA, Patterson BK, et al. In vivo migration and function of transferred HIV-1-speciflc cytotoxic T cells. Nat Med 1999, 5:34-41.
36. Walker CM, Moody DJ, Stites DP, Levy JA. CD8+ Lymphocytes can control HIV infection in vitro by suppressing virus replication. Science 1986, 234:1563-1566.
37. Levy JA, Mackewicz CE, Barker E. Controlling HIV pathogenesis: the role of the noncytotoxic anti-HIV response of CD8+ T cells. Immunol Today 1996, 17:217-224.
38. Cocchi F, De Vico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995, 270:1811-1815.
39. Akashi K, Kondo M, Weissman IL. Role of interleukin-7 in T-cell development from hematopoietic stem cells. Immunol Rev 1998, 165:13-28.
40. Hassan J, Reen DJ. IL-7 promotes the survival and maturation but not differentiation of human post-thymic CD4+ T cells. Eur J Immunol 1998, 28:3057-3065.
41. Fry TJ, Connick E, Landay A, et al. A potential role for IL-7 in homeostasis in HIV infected patients. In: 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA (USA), 30 January-2 February 2000 [Abstract LB1].
42. Clerici M, Saresella M, Colombo F, et al. T Lymphocyte maturation abnormalities in uninfected newborns and children with vertical exposure to HIV. Blood 2000, 96:3866-3871.
43. Napolitano LA, Grant RM, Deeks SG, et al. Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion: implications for T-cell homeostasis. Nat Med 2001, 7:73-79.